NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical results demonstrating anti-fibrotic effects with NV55 ...